Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy

PHASE4CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

November 2, 2017

Study Completion Date

November 2, 2017

Conditions
Polypoidal Choroidal Vasculopathy Without Active Polyp
Interventions
DRUG

aflibercept

"1. Three monthly intravitreal aflibercept (2mg) injections~2. Five bimonthly intravitreal aflibercept (2mg) injections~3. Rescue treatment: Verteporfin photodynamic therapy~ * Loss of five ETDRS letters or one Snellen line of vision from baseline~ * Presence of subretinal fluid or intraretinal fluid despite three consecutive (monthly or bimonthly) aflibercept injection~ * Presence of active polyp on indocyanine green angiography"

Trial Locations (3)

Unknown

Seoul National University Bundang Hospital, Seongnam

Konyang University Kim's Eye Hospital, Seoul

Samsung Medical Center, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Seoul National University Bundang Hospital

OTHER

collaborator

Kim's Eye Hospital

OTHER

collaborator

Bayer

INDUSTRY

lead

Samsung Medical Center

OTHER